Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Elekta AB (EKTAY : OTC)
 
 • Company Description   
Elekta AB is a human care company engaged in developing and selling clinical solutions for the treatment of cancer and neurological diseases. It develops tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. The Company's offering is divided into five areas: Neuroscience, Oncology, Software, Brachytherapy and Services. Elekta AB is headquartered in Stockholm, Sweden.

Number of Employees: 4,826

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.45 Daily Weekly Monthly
20 Day Moving Average: 4,195 shares
Shares Outstanding: 383.57 (millions)
Market Capitalization: $2,857.58 (millions)
Beta: 1.08
52 Week High: $8.65
52 Week Low: $4.68
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -11.63% -14.97%
12 Week -4.85% -11.68%
Year To Date 24.48% 13.23%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Kungstensgatan 18 P.O. Box 7593
-
Stockholm,V7 SE-103 93
SWE
ph: 46-8-587-254-00
fax: 46-8-587-255-00
kira.haapanen@elekta.com http://www.elekta.com
 
 • General Corporate Information   
Officers
Gustaf Salford - Chief Executive Officer and President
Laurent Leksell - Chairman of the Board
Tobias Hagglov - Chief Financial Officer
Cecilia Wikstrom - Director
Birgitta Stymne Goransson - Director

Peer Information
Elekta AB (ABMD)
Elekta AB (DMDS)
Elekta AB (CPWY.)
Elekta AB (EQUR)
Elekta AB (ECIA)
Elekta AB (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 28617Y101
SIC: 8071
Fiscal Year
Fiscal Year End: April
Last Reported Quarter: 07/01/22
Next Expected EPS Date: 06/07/23
Share - Related Items
Shares Outstanding: 383.57
Most Recent Split Date: (:1)
Beta: 1.08
Market Capitalization: $2,857.58 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 2.09%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.16
Current Fiscal Year EPS Consensus Estimate: $0.34 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/07/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 21.91
Trailing 12 Months: 22.58
PEG Ratio: -
Price Ratios
Price/Book: 3.18
Price/Cash Flow: 11.12
Price / Sales: 1.78
EPS Growth
vs. Year Ago Period: -50.00%
vs. Previous Quarter: -83.33%
Sales Growth
vs. Year Ago Period: -7.41%
vs. Previous Quarter: -26.40%
ROE
04/30/23 - -
01/31/23 - -
10/31/22 - -
ROA
04/30/23 - -
01/31/23 - -
10/31/22 - -
Current Ratio
04/30/23 - -
01/31/23 - -
10/31/22 - -
Quick Ratio
04/30/23 - -
01/31/23 - -
10/31/22 - -
Operating Margin
04/30/23 - -
01/31/23 - -
10/31/22 - -
Net Margin
04/30/23 - -
01/31/23 - -
10/31/22 - -
Pre-Tax Margin
04/30/23 - -
01/31/23 - -
10/31/22 - -
Book Value
04/30/23 - -
01/31/23 - -
10/31/22 - -
Inventory Turnover
04/30/23 - -
01/31/23 - -
10/31/22 - -
Debt-to-Equity
04/30/23 - -
01/31/23 - -
10/31/22 - -
Debt-to-Capital
04/30/23 - -
01/31/23 - -
10/31/22 - -
 

Powered by Zacks Investment Research ©